PANCREATIC NEUROENDOCRINE TUMOR
Clinical trials for PANCREATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for PANCREATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against tough cancers in early trial
Disease control OngoingThis Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…
Matched conditions: PANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Shorter antibiotics after pancreatic surgery may cut hospital stays
Disease control TerminatedThis study compares two approaches to prevent pancreatic leaks after Whipple surgery: giving antibiotics for a short time with a drug called octreotide versus giving antibiotics for a longer time. About 103 adults at intermediate or high risk for leaks will take part. The goal is…
Matched conditions: PANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2, PHASE3 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Matched conditions: PANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could abemaciclib be the next weapon against Hard-to-Treat gut tumors?
Disease control OngoingThis phase 2 trial tests the drug abemaciclib (Verzenio) in 20 patients with advanced gastroenteropancreatic neuroendocrine tumors that have spread, are not responding to treatment, and cannot be surgically removed. The drug works by blocking enzymes that help cancer cells grow. …
Matched conditions: PANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill shows promise for Hard-to-Treat neuroendocrine tumors
Disease control OngoingThis phase II trial is testing an oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The drug aims to slow tumor growth and improve disease control. Participants take the pill twice daily, with a possible dos…
Matched conditions: PANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Which scan spots hidden tumors best? new study aims to find out
Diagnosis OngoingThis study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 people with metastatic neuroendocrine tumors. The goal is to see if all tumors show up on the standard scan or if some are missed, which could change treatment. Participants will get …
Matched conditions: PANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: University of Alberta • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
Massive pancreatic surgery registry launches to improve patient care
Knowledge-focused OngoingThis registry collects information from 2000 people who have had pancreatic surgery for benign or malignant tumors. Researchers track complications and long-term results to understand what works best. The goal is to improve quality of care and support future research.
Matched conditions: PANCREATIC NEUROENDOCRINE TUMOR
Sponsor: University Hospital, Antwerp • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New biopsy test may predict pancreatic tumor danger
Knowledge-focused OngoingThis study looks at whether checking for two proteins, ATRX and DAXX, in biopsy samples can help predict how aggressive non-functional pancreatic neuroendocrine tumors (NF-pNETs) are. Researchers will compare biopsy results with surgical tissue from 100 adults to see if the test …
Matched conditions: PANCREATIC NEUROENDOCRINE TUMOR
Sponsor: Azienda Ospedaliera Universitaria Integrata Verona • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC